1. Academic Validation
  2. MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology

MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology

  • ACS Med Chem Lett. 2018 Jun 14;9(7):761-767. doi: 10.1021/acsmedchemlett.8b00220.
Sobhana Babu Boga 1 Yongqi Deng 2 Liang Zhu 2 Yang Nan 2 Alan B Cooper 1 Gerald W Shipps Jr 2 Ronald Doll 1 Neng-Yang Shih 1 Hugh Zhu 1 Robert Sun 1 Tong Wang 2 Sunil Paliwal 1 Hon-Chung Tsui 1 Xiaolei Gao 1 Xin Yao 1 Jagdish Desai 1 James Wang 1 Abdul Basit Alhassan 1 Joseph Kelly 1 Mehul Patel 2 Kiran Muppalla 2 Subrahmanyam Gudipati 1 Li-Kang Zhang 1 Alexei Buevich 1 David Hesk 1 Donna Carr 1 Priya Dayananth 1 Stuart Black 1 Hong Mei 1 Kathleen Cox 1 Bradley Sherborne 1 Alan W Hruza 1 Li Xiao 1 Weihong Jin 1 Brian Long 1 Gongjie Liu 1 Stacey A Taylor 1 Paul Kirschmeier 1 William T Windsor 1 Robert Bishop 1 Ahmed A Samatar 1
Affiliations

Affiliations

  • 1 Merck & Co., Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States.
  • 2 Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States.
Abstract

The emergence and evolution of new immunological Cancer therapies has sparked a rapidly growing interest in discovering novel pathways to treat Cancer. Toward this aim, a novel series of pyrrolidine derivatives (compound 5) were identified as potent inhibitors of ERK1/2 with excellent kinase selectivity and dual mechanism of action but suffered from poor pharmacokinetics (PK). The challenge of PK was overcome by the discovery of a novel 3(S)-thiomethyl pyrrolidine analog 7. Lead optimization through focused structure-activity relationship led to the discovery of a clinical candidate MK-8353 suitable for twice daily oral dosing as a potential new Cancer therapeutic.

Figures